Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

Journal of Clinical Pharmacology

Volumn 36, Issue 7, 1996, Pages 604-609

  Cilla Jr , Donald D ^a   Gibson, Donald M ^a   Whitfield, Lloyd R ^a   Sedman, Allen J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIVER TOXICITY; MALE; NIGHT; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SUNLIGHT;

EID: 9344235448     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04224.x     Document Type: Article

References (21)

1. Whitfield LR, Cilla DD Jr, Sedman AJ: Single- and multiple-dose pharmacokinetics of CI-981, a potent HMG-CoA reductase inhibitor (abstract). Pharm Res 1993;10:8-340.
2. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, et al: Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
3. Parker TS, McNamara DJ, Brown CD, Kolb R, Ahrens EH, Alberts AW, et al: Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest 1984;74:795-804.
4. Jones PJH, Schoeller DA: Evidence for diurnal periodicity in human cholesterol synthesis J Lipid Res 1990;31:667-673.
5. Parker TS, McNamara DJ, Brown C, Garrigan O, Kolb R, Batwin H, Ahrens EH: Mevalonic acid in human plasma: relationship of concentration and circadian rhythmn to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 1982;79:3037-3041.
6. Illingworth DR: Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther 1986;40:338-343.
7. Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y: Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects: a double-blind comparative study. Arterioscler Thromb 1991;11:816-826.
8. Hunninghake DB, Mellies MJ, Goldberg AC, Kuo PT, Kostis JB, Schrott HG, et al: Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once daily versus twice daily dosing. Atherosclerosis 1990;85:219-227.
9. Levy RI, Troendle AJ, Fattu JM: A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993;87(suppl III):III-45-III-53.
10. Shum YY, Huang H: Development and validation of an enzyme inhibition assay for quantitalion of CI-981 in human plasma (abstract). Pharm Res 1993;10:S-415.
11. Hunninghake DB: HMG CoA reductase inhibitors. Curr Opin Lipidol 1992;3:22-28.
12. Triscari J, Pan H, DeVault A, Rossi L, Smith S, Wang-Iverson D: Comparative bioavailability of pravastatin following morning and evening dosing (abstract PIII-19). Clin Pharmacol Ther 1991;49:178.
13. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT: Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993;6:375S-382S.
14. Quion JA, Jones PH: Clinical pharmacokinetics of pravastatin. Clin Pharmacokinel 1994;27:94-103.
15. McKenney J: Lovastatin: a new cholesterol-lowering agent. Clin Pharm 1988;7:21-36.
16. Lovastatin Study Group II: Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. JAMA 1986;256: 2829-2834.
17. Pan HY, DeVault AR, Brescia D, Willard WA: Comparative efficacy of once-daily versus twice-daily pravastatin in primary hypercholesterolemia. Clin Ther 1991;13:368-372.
18. Lovastatin Study Group IV: A mullicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. Am J Cardiol 1990;66:22B-30B.
19. Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, Tobert JA, et al: Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study. Ann Intern Med 1987;107:609-615.
20. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al: Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.
21. Insull W, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, et al: Efficacy and safety of once-daily versus twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994;154:2449-2455.